Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sue Haupt

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
F1000Research|December 19, 2017
P53 at the start of the 21st century: lessons from elephantsSue Haupt, Ygal Haupt
Anti-Cancer Drugs|August 24, 2006
Importance of p53 for cancer onset and therapySue Haupt, Ygal Haupt
Frontiers in Genetics|March 5, 2021
Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex DisparitySue Haupt, Ygal Haupt
Frontiers in Oncology|February 10, 2016
Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysSue Haupt, Dinesh Raghu, Ygal Haupt
Growth Factors (Chur, Switzerland)|October 26, 2005
Mdm2 in growth signaling and cancerYaara Levav-Cohen, Sue Haupt, Ygal Haupt
Trends in Cancer|December 10, 2019
Cannibalism in Breast Cancer: The Dangers of OvereatingSue Haupt, Simon P Keam, Ygal Haupt
Anti-Cancer Drugs|August 19, 2006
Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen speciesSue Haupt, Jackie Kleinstern, Ygal Haupt, et al.
FEBS Letters|February 20, 2014
PML tumour suppression and beyond: therapeutic implicationsCristina Gamell, Piotr Jan Paul, Ygal Haupt, et al.
Frontiers in Oncology|June 5, 2013
New Strategies to Direct Therapeutic Targeting of PML to Treat CancersKamil Wolyniec, Dennis A Carney, Sue Haupt, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 4, 2006
Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancerSue Haupt, Tamar Zioni, Irith Gati, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
F1000Research|December 19, 2017
P53 at the start of the 21st century: lessons from elephantsSue Haupt, Ygal Haupt
Anti-Cancer Drugs|August 24, 2006
Importance of p53 for cancer onset and therapySue Haupt, Ygal Haupt
Frontiers in Genetics|March 5, 2021
Cancer and Tumour Suppressor p53 Encounters at the Juncture of Sex DisparitySue Haupt, Ygal Haupt
Frontiers in Oncology|February 10, 2016
Mutant p53 Drives Cancer by Subverting Multiple Tumor Suppression PathwaysSue Haupt, Dinesh Raghu, Ygal Haupt
Growth Factors (Chur, Switzerland)|October 26, 2005
Mdm2 in growth signaling and cancerYaara Levav-Cohen, Sue Haupt, Ygal Haupt
Trends in Cancer|December 10, 2019
Cannibalism in Breast Cancer: The Dangers of OvereatingSue Haupt, Simon P Keam, Ygal Haupt
Anti-Cancer Drugs|August 19, 2006
Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen speciesSue Haupt, Jackie Kleinstern, Ygal Haupt, et al.
FEBS Letters|February 20, 2014
PML tumour suppression and beyond: therapeutic implicationsCristina Gamell, Piotr Jan Paul, Ygal Haupt, et al.
Frontiers in Oncology|June 5, 2013
New Strategies to Direct Therapeutic Targeting of PML to Treat CancersKamil Wolyniec, Dennis A Carney, Sue Haupt, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 4, 2006
Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancerSue Haupt, Tamar Zioni, Irith Gati, et al.
Pageof 6